erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer

D. Thor, Ann; A. Berry, Donald; R. Budman, Daniel; B. Muss, Hyman; E. Kute, Timothy; Craig Henderson, I.; Barcos, Maurice; Cirrincione, Constance; M. Edgerton, Susan; Allred, Craig; Norton, Larry; T. Liu, Edison

doi:10.1093/jnci/90.18.1346

Public

erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer

Published in JNCI Journal of the National Cancer Institute • Sep 16, 1998

Authors:

Ann D. Thor

Donald A. Berry

Daniel R. Budman

Abstract

BACKGROUND: We have previously reported that high expression of the erbB-2 gene (also known as HER-2/neu and ERBB2) in breast cancer is associated with patient response to dose-intensive treatment with cyclophosphamide, doxorubicin (Adriamycin), and 5-flurouracil (CAF) on the basis of short-term fol...

Subject

Medicine

Breast cancer

Immunohistochemistry

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!